A

Amgen

Makes biotech medicines for serious illnesses

Global Safety Associate Medical Director

Full-TimeUpdated on 10/22/2026
No salary listed
Expert
Bachelor's, MD
Hyderabad, Telangana, India
In Person
Biology & Biotech

About the job

Requirements
  • Knowledge of pharmacovigilance and risk-management processes and regulations, including interfaces among those processes.
  • Knowledge of drug development and lifecycle management, clinical and post-market safety data capture, and safety database structure and conventions.
  • Knowledge of MedDRA and other dictionaries used in pharmacovigilance.
  • Knowledge of qualitative and quantitative safety-data analysis, product and disease-state knowledge, general medicine, epidemiology, physiology, and pharmacology.
  • Knowledge of organizational and governance structures and the relationships among pharmacovigilance processes, reference safety information, and product labeling.
  • Skills in pharmacovigilance, signal detection and evaluation, aggregate data analysis, scientific judgment, medical concepts and terminology, document writing, source-document review, and data interpretation and synthesis.
  • Ability to apply statistical and epidemiological methods to pharmacovigilance, analyze and interpret complex safety data, and communicate complex scientific data clearly.
  • Strategic thinking; team and strategic leadership; influencing and negotiation in a cross-functional, matrix environment; contextual analysis; people and team management; conflict management; work organization, prioritization, and planning; project management; scientific assessment and problem solving; oral presentation; written and medical/scientific communication; and computer skills, including Microsoft Office and safety systems.
  • MBBS or equivalent degree from an accredited medical school.
  • Completion of an accredited medical or surgical residency, or clinical experience in an accredited academic, private-practice, or hospital-based setting.
  • Preferred: MBBS or equivalent degree from an accredited medical school; 12 years of directly related experience or an MD from a foreign medical school; product-safety experience in the biopharmaceutical industry, a contract research organization, or a regulatory agency; previous management and/or mentoring experience; and clinical experience in an accredited academic, private-practice, or hospital-based setting.
Responsibilities
  • Serve as safety expert for assigned marketed products and establish pharmacovigilance strategy, direction, and priorities; own the overall safety profile and product-related decisions and deliverables.
  • Lead the Safety Analysis Team and Global Safety Team, participate as a core member of the Executive Safety Committee and as a member of the Evidence Generation Team, and serve as a delegate for the Therapeutic Area Head as needed.
  • Maintain core reference safety information, including relevant portions of the Core Data Sheet; identify relevant data and conduct benefit-risk evaluations; participate in product labeling.
  • Develop strategies for safety-related portions of informed consent forms and other post-marketing trial documents, and lead preparation of responses to safety inquiries from regulatory agencies and ethics committees.
  • Perform signal-detection activities for developmental products under the direction of the Global Safety Officer responsible for the product in development.
  • Develop signal-detection strategy; evaluate findings, validate signals, determine whether further analysis is needed, and develop strategies for further analysis.
  • Decide whether further action is needed on safety issues and lead cross-functional discussions; document work in the safety information management system.
  • Prepare and present safety recommendations to the Global Safety Team and escalate issues to the executive-level cross-functional decision-making body as appropriate; approve safety assessment reports.
  • Search and review adverse-event data, literature, and other safety-relevant data for signal detection as needed.
  • Ensure timely preparation, content, and quality of new or updated risk-management plan documents; develop global safety-risk minimization strategies, including U.S. REMS when applicable, and develop additional risk-minimization materials as applicable.
  • Ensure timely preparation and quality of periodic safety reports, including PSUR/PBRER, and review and approve those reports.
  • Participate in safety-governance meetings, including facilitating, chairing, and presenting, in accordance with standard operating procedures and manuals.
  • Represent and contribute on behalf of Global Patient Safety to Evidence Generation Teams.
  • Perform activities delegated by the Qualified Person Responsible for Pharmacovigilance as detailed in the Pharmacovigilance System Master File and maintain inspection readiness; serve as representative and point of contact for health-authority inspections and internal process audits within the role's remit.
  • Participate in safety-agreement development and review; prepare safety information for licensing partners, review their safety documents, and communicate with them on safety matters under the agreement.
  • Perform safety due diligence for partnerships and participate in integration activities.
  • Interact with external stakeholders on safety topics, prepare for and participate in regulatory-agency advisory committees, and provide safety input for legal needs.
  • Oversee day-to-day activities of the Global Safety Physician, if applicable; ensure staff comply with corporate and departmental training and standard operating procedure review.
  • Train, coach, mentor, and develop staff; assist in recruiting Global Patient Safety and Amgen staff; communicate corporate and departmental information to staff and ensure understanding and adherence to changes.
  • Create staff development plans annually and review them quarterly.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.